Literature DB >> 8800323

Interstitial radiotherapy of 25 parasellar/clival meningiomas and 19 meningiomas in the elderly. Analysis of short-term tolerance and responses.

V Vuorinen1, J Heikkonen, A Brander, K Setälä, T Sane, T Randell, A Paetau, J Pohjola, M Mäntylä, J Jääskeläinen.   

Abstract

I-125 seeds were permanently implanted into 25 parasellar-clival meningiomas (median age of patients, 56 y) and 19 globoid meningiomas in the elderly (median age of patients, 77 y) using stereotactic technique and 3-D dose planning. Total dose at the tumour margin was increased during the series from 100 Gy to 150 Gy. The procedure caused no mortality and no serious bleeding, but injury to the III cranial nerve due to puncture occurred in one (4%) of the 25 parasellar-clival meningiomas. In two (4.5%) of the 44 cases the postoperative CT scan showed a misplaced seed, located at the tumour surface. Nonenhancing hypodense rings developed around the seeds ('hot spots') with a median diameter of 10.5 mm at 12 months corresponding to a median initial activity of 8.7 mCi. In general, meningiomas responded by slow reduction in volume. The parasellar-clival meningiomas were followed-up for a median of 19 months (6-32), and so far 4 tumours have shrunk moderately, 13 slightly, and 5 not at all. Pre-operative III, V or VI cranial nerve signs were present in 17 patients and subsided in 8 of them. On the other hand, facial numbness developed or increased in 9 of the 25 patients, indicating that the V nerve is rather sensitive to this type of irradiation. In the 19 meningiomas of the elderly, the median follow-up time was 14 months (5-26). The median relative tumour volume was 46% at 12 months. Accounting for tumour-related deaths only, the actuarial survival rate was 78% at 12 months and 62% at 24 months. In general, brain oedema persisted despite reduction in tumour volume. Stereotactic implantation of I-125 seeds into intracranial meningiomas is relatively safe. Interstitial radiotherapy represents a potential tool in the control of medium-sized intracranial meningiomas with minimal brain oedema, but its long-term impact and untoward effects remain to be followed-up.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800323     DOI: 10.1007/bf01411167

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  23 in total

1.  The combined supra- and infratentorial approach for lesions of the petrous and clival regions: experience with 46 cases.

Authors:  R F Spetzler; C P Daspit; C T Pappas
Journal:  J Neurosurg       Date:  1992-04       Impact factor: 5.115

2.  The dosimetry of 125I seed eye plaques.

Authors:  K A Weaver
Journal:  Med Phys       Date:  1986 Jan-Feb       Impact factor: 4.071

3.  Surgical excision of meningiomas involving the clivus: preoperative and intraoperative features as predictors of postoperative functional deterioration.

Authors:  L N Sekhar; N K Swamy; V Jaiswal; E Rubinstein; W E Hirsch; D C Wright
Journal:  J Neurosurg       Date:  1994-12       Impact factor: 5.115

4.  Stereotactic radiosurgery for acoustic nerve tumors in patients with useful preoperative hearing: results at 2-year follow-up examination.

Authors:  O K Ogunrinde; L D Lunsford; J C Flickinger; D Kondziolka
Journal:  J Neurosurg       Date:  1994-06       Impact factor: 5.115

5.  Role of brachytherapy in the management of the skull base meningioma. Treatment of skull base meningiomas.

Authors:  P P Kumar; A A Patil; H W Syh; W K Chu; M A Reeves
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

6.  Outcome of aggressive removal of cavernous sinus meningiomas.

Authors:  F DeMonte; H K Smith; O al-Mefty
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

7.  Surgery of petroclival meningiomas: report of 24 cases.

Authors:  M Samii; M Ammirati; A Mahran; W Bini; A Sepehrnia
Journal:  Neurosurgery       Date:  1989-01       Impact factor: 4.654

Review 8.  High activity iodine 125 endocurietherapy for recurrent skull base tumors.

Authors:  P P Kumar; R R Good; L G Leibrock; J R Mawk; A J Yonkers; F P Ogren
Journal:  Cancer       Date:  1988-04-15       Impact factor: 6.860

9.  Continuous low dose rate brachytherapy with high activity iodine-125 seeds in the management of meningiomas.

Authors:  P P Kumar; A A Patil; L G Leibrock; W K Chu; H W Syh; G F McCaul; M A Reeves
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-01-15       Impact factor: 7.038

10.  Brachytherapy: a viable alternative in the management of basal meningiomas.

Authors:  P P Kumar; A A Patil; L G Leibrock; W K Chu; J Syh; G F McCaul; M A Reeves
Journal:  Neurosurgery       Date:  1991-11       Impact factor: 4.654

View more
  2 in total

1.  Brachytherapy as an Adjuvant for Recurrent Atypical and Malignant Meningiomas.

Authors:  Matthew J Koch; Pankaj K Agarwalla; Trevor J Royce; Helen A Shih; Kevin Oh; Andrezj Niemierko; Thomas C Mauceri; William T Curry; Frederick G Barker; Jay S Loeffler
Journal:  Neurosurgery       Date:  2019-11-01       Impact factor: 4.654

Review 2.  Iodine-125 brachytherapy for brain tumours--a review.

Authors:  Silke B Schwarz; Niklas Thon; Katharina Nikolajek; Maximilian Niyazi; Joerg-Christian Tonn; Claus Belka; Friedrich-Wilhelm Kreth
Journal:  Radiat Oncol       Date:  2012-03-06       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.